New obesity option for teens, Wegovy brings Novo Nordisk’s GLP-1 to younger patients

Novo Nordisk’s once-weekly Wegovy injection, already a best-selling obesity drug in adults, is now also approved in the US for certain adolescents. What the higher-dose semaglutide offers, how it is used, and where it fits in Novo Nordisk’s broader obesity portfolio.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 1:15 PM ET. Details in the imprint.

Once a niche topic in diabetes clinics, obesity treatment has become a mass market - and Novo Nordisk’s Wegovy is now reaching younger patients as well. The once-weekly semaglutide injection, already a blockbuster in adults with obesity, gained US approval in December 2022 for use in adolescents 12 years and older with obesity, when combined with lifestyle interventions such as diet and physical activity, expanding the company’s reach in this fast-growing therapeutic area. The GLP-1 analog targets chronic weight management, not short-term dieting, and is positioned by the manufacturer as a long-term medical tool rather than a cosmetic quick fix.

What Wegovy does and how the higher-dose semaglutide works

Wegovy is a brand name for semaglutide formulated specifically for chronic weight management and given as a once-weekly subcutaneous injection at doses titrated up to 2.4 mg, which is higher than the 1.0 mg typically used in Ozempic for type 2 diabetes therapy. The medicine is a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking an intestinal hormone that increases insulin secretion, slows gastric emptying and reduces appetite, leading to lower calorie intake and, in many patients, sustained weight loss over time. In pivotal STEP clinical trials in adults with obesity or overweight and weight-related comorbidities, Wegovy reduced mean body weight by around 15 percent from baseline over 68 weeks, significantly more than placebo on top of lifestyle counseling, and a portion of patients achieved weight reductions of 20 percent or more, underlining its potency relative to older anti-obesity drugs. The drug is intended for adults with a body mass index (BMI) of 30 or greater, or 27 or greater with at least one weight-related condition such as hypertension, type 2 diabetes or dyslipidemia, and it requires gradual dose escalation over several weeks to improve tolerability.

For adolescents, the US label covers patients 12 years and older with obesity defined using standardized BMI metrics, and the safety and efficacy profile was evaluated in a 68-week trial where Wegovy-treated teens showed clinically meaningful reductions in BMI compared with placebo under lifestyle counseling. In both adults and adolescents, the most common side effects involve the gastrointestinal tract, including nausea, diarrhea, vomiting and constipation, particularly during dose escalation, while more serious but less frequent risks such as gallbladder problems, pancreatitis and potential thyroid C-cell tumors are highlighted in the prescribing information and risk profile. Novo Nordisk presents Wegovy as part of a comprehensive treatment plan that includes nutritional guidance and increased physical activity, and prescribers are advised to monitor patients for mental health symptoms including suicidal ideation as part of the broader risk management for obesity pharmacotherapy. Because the drug slows gastric emptying and causes potent satiety, physicians are also paying attention to the potential impact on other orally administered drugs and on perioperative management, a topic that has drawn scrutiny as GLP-1 use expands beyond traditional diabetes settings.

Wegovy is supplied in single-use, prefilled injection pens designed for once-weekly self-administration, with fixed-dose devices ranging from 0.25 mg for initiation up to 2.4 mg for maintenance, allowing patients or caregivers to inject in the abdomen, thigh or upper arm after brief training. The pen design borrows from Novo Nordisk’s long experience with insulin and GLP-1 injection devices, and the company emphasizes ease of use and discreet handling as a differentiator in a segment where adherence can be undermined by complex dosing schedules or injection anxiety. In the US, Wegovy is available by prescription and its list price is high by primary-care standards, but net prices vary widely depending on insurance coverage, prior authorization rules and patient assistance programs; many commercial health plans now cover at least some GLP-1 obesity drugs, while coverage in public plans remains patchier. The drug’s entry into adolescent care has intensified debate among pediatricians and public health experts about the medicalization of youth obesity versus lifestyle-first approaches, yet guideline bodies such as the American Academy of Pediatrics are increasingly open to pharmacotherapy as an adjunct in severe cases where diet and exercise alone have not been sufficient.

Competition is not standing still: Eli Lilly’s tirzepatide (Mounjaro for diabetes, Zepbound for obesity) has shown even greater mean weight loss in adult trials, raising questions about how long Wegovy can maintain first-mover advantage among GLP-1-based obesity therapies. Novo Nordisk is therefore investing in new-generation compounds and fixed-dose combinations, as well as expanding manufacturing capacity to ease ongoing supply constraints that have limited Wegovy availability in multiple markets and forced the company to prioritize certain dose strengths and patient segments. Demand has been particularly strong in the US, where obesity prevalence is high and direct-to-consumer marketing plus social media interest in GLP-1 drugs have accelerated uptake beyond early expectations. For Novo Nordisk, Wegovy is more than a single product: it anchors a broader strategy to reposition the company from a pure diabetes specialist to a wider metabolic-disease and cardiometabolic player, including cardiovascular risk reduction indications that could further expand the eligible patient pool.

Within Novo Nordisk’s portfolio, Wegovy complements diabetes-focused semaglutide brands such as Ozempic and oral Rybelsus, but it is specifically labeled for weight management and marketed through a combination of endocrinologists, obesity specialists and primary care physicians. The company highlights not only weight loss but also improvements in cardiometabolic markers such as blood pressure and lipids observed in clinical trials, positioning the drug as a tool to reduce downstream cardiovascular risk in high-BMI populations. At the same time, the significant cost and injection route mean that Wegovy is unlikely to replace lifestyle interventions; instead, clinicians are deploying it as second- or third-line therapy in patients who have not succeeded with diet and exercise alone, and in many cases using it as a bridge to bariatric surgery or as an alternative for patients unwilling or unable to undergo surgical procedures. Payers are still defining reimbursement rules, often demanding documentation of previous weight-loss attempts, and real-world effectiveness data will shape how coverage evolves over the next several years.

For Novo Nordisk, the youth indication strengthens Wegovy’s role as a flagship growth driver alongside its established diabetes franchise, contributing materially to revenue and to the company’s positioning in the global obesity market. Shares of Novo Nordisk A/S (DK0062498333) traded on the New York Stock Exchange at around $138 on 06/14/2026, reflecting investor expectations that GLP-1 obesity drugs such as Wegovy will underpin medium-term growth and margin expansion.

Wegovy weight-loss injection in brief

• Product: Wegovy (semaglutide) injection
• Manufacturer: Novo Nordisk A/S
• Category: New Release/Launch - obesity treatment
• Launch date: Initial US adult approval June 2021; US adolescent indication December 2022
• MSRP / Price: Prescription-only, list price high and payer-dependent in USD
• Availability: Prescription in the US and selected international markets, with periodic supply constraints
• Target audience: Adults and adolescents 12+ with obesity or overweight with weight-related conditions
• Key differentiator / USP: Once-weekly GLP-1 analog with high average weight loss in clinical trials

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.